The cancer diagnostics company, after a trading halt this morning, says it should get better prices for its tests in the US if Medicare funding can be restored.
An optimistic update from cancer diagnostics company Pacific Edge gave its shares a boost after a trading halt this morning interrupted investor gloom over bad news from the US.
In a statement to the NZX, Pacific Edge said it had been notified its Triage Plus product could receive a price of US$1018
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive FREE offer for uni students studying at a New Zealand university (valued at $499).
